PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Loteprednol etabonate - Postoperative pain and inflammation (eye)
PAD Profile : Loteprednol etabonate - Postoperative pain and inflammation (eye)
Keywords :
Brand Names Include :
Lotemax
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agrees that loteprednol etabonate eye drops should only be used on a short-term basis (maximum of 2 weeks duration) to treat post-operative inflammation as per its product license.
Therefore, loteprednol etabonate a RED traffic light status is agreed by APC.
Sufficient quantities should be supplied through secondary care as part of a package of post-operative care.”
Associated BNF Codes
11. Eye
11.04.01. Corticosteroids